ARCHIVES

Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

In Brief: George Vande Woude Of NCI Named PI for Litton Bionetics Basic Research Contract At Frederick

September 23, 1983

Cancer Care Driven Toward: Triage” System, Puerto Rico Dean Tells AACI

July 21, 1989

In Brief: NCI’s George Khoury Dies; Panel to Meet June 22 In Pittsburgh; Rosemary Mackey To Leave MDA

May 8, 1987

FDA Advisors: DepoCyt May Test Accelerated Approval Mechanism

November 27, 1998

Obey Explains Cuts In Control, Construction Funds; House Passes HEW Appropriations Bill

July 6, 1979

Drug Approvals: FDA Approves Vectibix in mCRC With KRAS Companion Diagnostic

May 30, 2014